Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02172495

Enrollment

4700

Registered

2014-06-24

Start date

2002-06-30

Completion date

Unknown

Last updated

2018-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Brief summary

Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.

Interventions

DRUGTiotropium bromide

Tiotropium bromide 18 micrograms

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men and women aged at least 40 years with the symptoms of Chronic Obstructive Pulmonary Disease

Exclusion criteria

* Patients with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information

Design outcomes

Primary

Measure	Time frame
Change from baseline in breathlessness when walking/climbing stairs	Baseline, after 4 weeks
Change from baseline in breathlessness on physical exercise	Baseline, after 4 weeks
Change from baseline in breathlessness during everyday activities	Baseline, after 4 weeks
Change from baseline in breathlessness during housework	Baseline, after 4 weeks
Change from baseline in overall severity of the clinical picture	Baseline, after 4 weeks
Occurrence of Adverse Events	4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026